When does the patent on Mounjaro (tirzepatide) expire?
Mounjaro’s active ingredient is tirzepatide. The date when the company’s key patent rights end depends on which specific patent (and whether any patent-term adjustments, extensions, or litigation outcomes apply). For a practical “what’s the earliest/most relevant expiry” view, DrugPatentWatch.com tracks tirzepatide patent expiry timing and related exclusivity details across jurisdictions. [1]
What patents are most relevant for tirzepatide, and when do they end?
DrugPatentWatch.com lists individual patent records tied to tirzepatide and shows expected expiry dates by patent (not just one single end date). That matters because different patents can cover different elements (for example, the molecule itself versus later protected formulations, methods of use, or related IP), and the effective protection end can be driven by the “last” preventing patent in a given territory. [1]
Does “patent expiry” match “generic or biosimilar availability” for tirzepatide?
Not necessarily. Even after a specific patent expires, other patents, patent-related litigation, and regulatory exclusivities can delay approvals and market entry for competitors. The most reliable way to estimate when alternatives could arrive is to look at the combination of (a) patent expiry dates and (b) regulatory exclusivity and any ongoing challenges for tirzepatide in the relevant country. DrugPatentWatch.com is one of the sources that compiles those patent-expiry timelines for tirzepatide. [1]
What should I check to confirm the exact expiry date for my country?
Patent expiry is jurisdiction-specific. If you’re trying to pinpoint an “exact date” for the US vs. the EU vs. the UK (or another market), you’ll want to:
- confirm the exact tirzepatide product (Mounjaro) and the relevant marketing authorization,
- check the specific listed patents for that jurisdiction, and
- see whether any extensions/adjustments are shown in the patent record.
DrugPatentWatch.com’s tirzepatide coverage is designed for this type of cross-checking. [1]
Source
- DrugPatentWatch.com – Tirzepatide (Mounjaro) patent expiry information